NCT05005910View on ClinicalTrials.gov

Efficacy of Vonoprazan Versus Intravenous Proton Pump Inhibitors for Prevention of Rebleeding in High Risk Peptic Ulcers Bleeding After Successful Endoscopic Hemostasis

EARLY_PHASE1CompletedINTERVENTIONAL

Enrollment

194

Participants

Timeline

Start Date

September 1, 2021

Primary Completion Date

December 1, 2022

Study Completion Date

December 1, 2022

Conditions

Peptic Ulcer With Haemorrhage

Interventions

DRUG

Vonoprazan

Vonoprazan 20 mg oral every 12 hours (total 72 hours)

DRUG

PPIs IV infusion

Pantoprazole 80 mg IV loading then 8 mg/hr

Trial Locations (1)

10700

Faculty of internal medicine siriraj hospital, Mahidol university, Bangkok Noi

All Listed Sponsors

lead

Uayporn Kaosombatwattana

OTHER

NCT05005910 - Efficacy of Vonoprazan Versus Intravenous Proton Pump Inhibitors for Prevention of Rebleeding in High Risk Peptic Ulcers Bleeding After Successful Endoscopic Hemostasis | Biotech Hunter | Biotech Hunter